SPOTLIGHT -
Dr. Cohen on the Efficacy of Cilta-Cel in Lenalidomide-Refractory Multiple Myeloma
Adam D. Cohen, MD, discusses the efficacy of ciltacabtagene autoleucel in patients with lenalidomide-refractory multiple myeloma.
Read More
Dr. Cohen on the Safety Profile of Cilta-Cel in Multiple Myeloma
Adam D. Cohen, MD, discusses the safety profile of ciltacabtagene autoleucel in patients with multiple myeloma, based on data from the phase 2 CARTITUDE-2 study.
Dr. Cohen on CARTITUDE-2 Data With Cilta-Cel in Multiple Myeloma
Adam D. Cohen, MD, discusses outcomes with ciltacabtagene autoleucel, as demonstrated in the phase 2 CARTITUDE-2 study in patients with multiple myeloma.
Dr. Cohen on Mitigation Strategies for CAR T-Cell Therapy in Multiple Myeloma
Adam D. Cohen, MD, discusses mitigation strategies that can be used for patients with relapsed/refractory multiple myeloma who are receiving the CAR T-cell therapy ciltacabtagene autoleucel.
Dr. Cohen on the DREAMM-2 Trial in Multiple Myeloma
Adam D. Cohen, MD, discusses the ongoing phase II DREAMM-2 study in multiple myeloma.
Second-Line Treatment of R/R LBCL With Lisocabtagene Maraleucel (Liso-cel)
ZUMA-7: Axicabtagene Ciloleucel as a Second-Line Therapy for LBCL
Currently Available Treatment Options for Patients With R/R DLBCL
Overview of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)